Sumitomo Pharmaceuticals Co., Ltd.

Osaka Pharmaceuticals Co., Ltd. was established by 21 prominent leaders in the pharmaceutical industry in Doshomachi, Osaka in 1897.

Osaka Pharmaceuticals Co., Ltd. was established by 21 prominent leaders in the pharmaceutical industry in Doshomachi, Osaka in 1897.

In the following year of 1898, the Pharmaceutical Plant was established in Ebie, Osaka. The company acquired the semi‑governmental Dainippon Pharmaceutical Company in Tokyo, and changed the name of the company to Dainippon Pharmaceutical Co., Ltd.

In the following year of 1898, the Pharmaceutical Plant was established in Ebie, Osaka.

Sumitomo Pharmaceuticals Co., Ltd. was established in 1984 from the Research, Development and Manufacturing divisions of Sumitomo Chemical Co., Ltd.’s pharmaceuticals business, as well as the Pharmaceutical Sales division of Inabata & Co., Ltd., the sole distributor of Sumitomo Chemical Company’s pharmaceuticals.

Acquired Sepracor Inc. (currently, Sumitomo Pharma America Inc.) in order to build in‑house development and marketing systems of the atypical antipsychotic developed in‑house in the U.S.

Acquired Boston Biomedical, Inc. (currently, Sumitomo Pharma America Inc.), a US biotech company specializing in oncology area. Gained superb capability to discover and develop drugs in the area of oncology.

Completion of “SMaRT,” a World First Manufacturing Plant for Regenerative Medicine & Cell Therapy. Completed “SMaRT,” a manufacturing plant for regenerative medicine & cell therapy - the world’s first facility dedicated to the commercial manufacture of regenerative medicine and cell therapy products derived from allogeneic iPS cells, which makes the manufacture of investigational agents as well as early‑stage commercial production possible -within our Central Research Laboratories.

Completed “SMaRT,” a manufacturing plant for regenerative medicine & cell therapy - the world’s first facility dedicated to the commercial manufacture of regenerative medicine and cell therapy products derived from allogeneic iPS cells, which makes the manufacture of investigational agents as well as early‑stage commercial production possible -within our Central Research Laboratories.

Accelerating Growth through Strategic Alliance with Roivant Sciences Ltd. Concluded the Agreement for Strategic Alliance with Roivant Sciences Ltd., thereby acquiring numerous pipeline assets, including those that have the potential to become blockbusters in the future, as well as DrugOME and Digital Innovation, the healthcare technology platforms which will accelerate our digital transformation (DX), and certain key employees.

Concluded the Agreement for Strategic Alliance with Roivant Sciences Ltd., thereby acquiring numerous pipeline assets, including those that have the potential to become blockbusters in the future, as well as DrugOME and Digital Innovation, the healthcare technology platforms which will accelerate our digital transformation (DX), and certain key employees. We accelerated our DX and pressed ahead with our “transformation into a data‑driven pharmaceutical company” as well as “creation of new value and operational reform,” with a view to attaining sustained growth.

Establishment of S‑RACMO, a Joint Venture for CDMO Business in the Field of Regenerative Medicine/Cell Therapy. Established S‑RACMO Co., Ltd., a joint venture with Sumitomo Chemical, to develop manufacturing methods and manufacture products for the field of regenerative medicine/cell therapy and to undertake business as a Contract Development and Manufacturing Organization (CDMO).

Change of the Trade Name to 'Sumitomo Pharma Co., Ltd.' Changed the trade name from 'Sumitomo Dainippon Pharma' to 'Sumitomo Pharma' and refreshed the Group’s identity under the globally recognized 'Sumitomo' brand, to achieve continuous growth and advance to a new stage, amid the globalization of business, entry into new research areas such as oncology, and numerous challenges including large‑scale acquisitions and partnerships.

Changed the trade name from “Sumitomo Dainippon Pharma” to “Sumitomo Pharma” and refreshed the Group’s identity under the globally recognized “Sumitomo” brand, to achieve continuous growth and advance to a new stage, amid the globalization of business, entry into new research areas such as oncology, and numerous challenges including large‑scale acquisitions and partnerships.

Establishment of RACTHERA Co., Ltd., the Regenerative Medicine and Cell Therapy Business Joint Venture. Established RACTHERA Co., Ltd., a joint venture with Sumitomo Chemical, to accelerate the commercialization of regenerative medicine/cell therapy within the Sumitomo Chemical Group. With personnel primarily seconded from Sumitomo Pharma, RACTHERA, together with Sumitomo Chemical, Sumitomo Pharma.

Established RACTHERA Co., Ltd., a joint venture with Sumitomo Chemical, to accelerate the commercialization of regenerative medicine/cell therapy within the Sumitomo Chemical Group. With personnel primarily seconded from Sumitomo Pharma, RACTHERA, together with Sumitomo Chemical, Sumitomo Pharma, and S‑RACMO, is working as one to advance research and development in regenerative medicine/cell therapy, aiming to deliver new treatment options to patients as quickly as possible.